Overview

* Stevanato Q2 2025 revenue grows 8% yr/yr, beating analysts' expectations

* Net income for Q2 beats analyst estimates

* Company maintains fiscal 2025 guidance, indicating confidence in strategic plans

Outlook

* Stevanato maintains fiscal 2025 revenue guidance of €1.160 bln to €1.190 bln

* Company expects 2025 adjusted EBITDA between €288.5 mln and €301.8 mln

* Stevanato forecasts 2025 adjusted diluted EPS of €0.50 to €0.54

* Company says demand driven by pharmaceutical innovation and biologics

Result Drivers

* BDS SEGMENT GROWTH - 10% increase in Biopharmaceutical and Diagnostic Solutions segment revenue driven by high-value syringes and increased production capacity at Latina and Fishers facilities

* HIGH-VALUE SOLUTIONS - High-value solutions, including syringes, EZ-fill cartridges, and vials, represented 42% of total revenue, contributing significantly to qtr growth

* ENGINEERING SEGMENT DECLINE - 2% revenue decline in Engineering Segment due to lower revenue from glass converting and unfavorable project mix

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat EUR 280 EUR

Revenue mln 268.30

mln (9

Analysts

)

Q2 Net Beat EUR EUR

Income 29.70 29.20

mln mln (9

Analysts

)

Q2 Beat EUR EUR 40

Operatin 41.40 mln (9

g Income mln Analysts

)

Q2 Beat EUR EUR

Pretax 39.10 37.30

Profit mln mln (7

Analysts

)

Q2 Basic EUR 0.11

EPS

Q2 Gross EUR

Profit 78.60

mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Stevanato Group SpA ( STVN ) is $28.00, about 8.6% above its August 4 closing price of $25.58

* The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)